

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA

CASE NO. 12-60862-CIV-MIDDLEBROOKS/BRANNON

SHIRE DEVELOPMENT LLC,
SHIRE PHARMACEUTICAL
DEVELOPMENT INC.,
COSMO TECHNOLOGIES LIMITED and
GIULIANI INTERNATIONAL LIMITED,

Plaintiffs,

v.

WATSON PHARMACEUTICALS, INC.,
WATSON LABORATORIES, INC. –
FLORIDA, WATSON PHARMA, INC., and
WATSON LABORATORIES, INC.,

Defendants.

FINAL JUDGMENT

In accordance with this Court's March 25, 2016 Opinion and Order, and the undisturbed findings of the Court's 2013 Order (DE 246), it is hereby

ORDERED AND ADJUDGED that Final Judgment is **ENTERED** in favor of Plaintiffs¹ and against Defendants² as follows:


1. U.S. Patent No. 6,773,720 (the "'720 Patent") is not invalid under 35 U.S.C. § 112 for lack of written description and/or enablement.
2. The filing of Abbreviated New Drug Application ("ANDA") No. 203817 was an act of infringement of the '720 Patent by Defendants.

¹ "Plaintiffs" refers to: Shire Development LLC; Shire Pharmaceutical Development, Inc.; Cosmo Technologies Limited; and Nogra Pharma Limited (f/k/a Giuliani International Limited).

² Defendants" refers to: Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.); Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.; and Watson Laboratories, Inc.

3. Any commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the products that are the subject of ANDA No. 203817 by Defendants prior to the expiration of the '720 Patent will constitute an act of infringement of the '720 Patent.
4. The effective date of any approval of the product that is the subject of ANDA No. 203817 shall be no earlier than the date on which the '720 Patent expires.
5. Defendants are preliminarily and permanently enjoined from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the products that are the subject of ANDA No. 203817 prior to the expiration of the '720 Patent.
6. Watson Pharmaceuticals, Inc. has, is, and will induce and/or contribute to Watson Laboratories, Inc.—Florida's, Watson Pharma, Inc.'s, and Watson Laboratories, Inc.'s infringement of the '720 patent.
7. The commercial manufacture, use, sale, offer for sale and/or importation into the United States of any products that are the subject of ANDA No. 203817 would induce and/or contribute to third-party infringement of the '720 patent.

DONE AND ORDERED in Chambers at West Palm Beach, Florida, this 25 day of March, 2016.



DONALD M. MIDDLEBROOKS
UNITED STATES DISTRICT JUDGE

Copies to: Counsel of Record